Please login to the form below

Not currently logged in
Email:
Password:

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Hudson named Brandicourt’s successor as Sanofi’s CEO

Hudson named Brandicourt’s successor as Sanofi’s CEO

atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).

Latest news

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    bid for Ablynx in December, which the Ablynx Board rejected.  Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics